Public data and media reports point to a surge in demand for antigen detection kits in my country in recent days as the country shifts from large-scale nucleic acid testing to a flexible approach to fighting the COVID-19 virus.
According to domestic media reports, on the domestic pharmaceutical products website JD Health, the turnover of antigen detection kits increased by 344% from November 28 to December 4 compared with the previous week.
At the same time, recently, many investors have raised questions about COVID-19 antigen detection kits to listed companies on the investor interaction platform. Many companies revealed to the media that the demand for kits has surged recently.
Rollmed, for example, said demand has grown since Jiangsu adjusted local coronavirus precautions.
"We produce about 7.5 million sets of these kits every day and ship them on the same day as the production, and the company currently has no stock in stock," the report quoted a staff member as saying. The report pointed out that the company will adjust production according to demand in the future.
The report pointed out that Zhejiang Gene Biotechnology Co., Ltd. also disclosed that the production of the company's COVID-19 antigen detection kit is rising due to the surge in demand.
So far, the NMPA has approved 36 COVID-19 antigen detection products.
Demand for COVID-19 antigen test kits surged after several Chinese local governments optimized coronavirus prevention policies and removed nucleic acid testing requirements in public places. Many Malaysians have been scrambling to buy products and related medicines in case of symptoms such as cough or fever.